Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🤖 ML Fraud Detection Score: 95%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
22,508
Total Claims
$2.4M
Drug Cost
1,119
Beneficiaries
$2,145
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-9%
Opioid rate vs peers
2.0% vs 2.2% avg
+52%
Cost per patient vs peers
$2,145 vs $1,411 avg
+32%
Brand preference vs peers
14.0% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
2.0%
Opioid Rate
458
Opioid Claims
$2,881
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,102 claims · $2.0M
Generic: 19,057 claims · $389K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 115 | $184K |
| Apixaban | 188 | $177K |
| Sitagliptin Phosphate | 126 | $138K |
| Fluticasone/Vilanterol | 191 | $111K |
| Fluticasone/Umeclidin/Vilanter | 150 | $109K |
| Insulin Glargine,hum.Rec.Anlog | 173 | $108K |
| Rivaroxaban | 77 | $97K |
| Insulin Aspart | 77 | $78K |
| Dulaglutide | 44 | $62K |
| Insulin Detemir | 49 | $61K |
| Empagliflozin | 46 | $51K |
| Sacubitril/Valsartan | 52 | $50K |
| Insulin Lispro | 43 | $49K |
| Linaclotide | 42 | $44K |
| Insulin Degludec | 48 | $31K |
Prescribing Profile
Patient Profile
71
Avg Age
57%
Female
1.53
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About